Biocryst Pharmaceuticals Inc [BCRX] stock prices are up 0.25% to $8.07 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCRX shares have gain 5.63% over the last week, with a monthly amount drifted -2.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] stock has seen the most recent analyst activity on February 25, 2025, when Wedbush initiated its Outperform rating and assigned the stock a price target of $15. On September 18, 2023, upgrade upgraded it’s rating to Outperform and revised its price target to $10 on the stock. Jefferies upgraded its rating to a Buy but stick to its price target of $11 on August 04, 2023. BofA Securities upgraded its rating to a Buy but $10 remained the price target by the analyst firm on July 13, 2023. Needham upgraded its rating to Buy for this stock on February 22, 2023, but kept the price target unchanged to $14. In a note dated November 02, 2022, Evercore ISI upgraded an Outperform rating on this stock and boosted its target price from $14 to $16.
The stock price of Biocryst Pharmaceuticals Inc [BCRX] has been fluctuating between $4.03 and $9.50 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] shares were valued at $8.07 at the most recent close of the market. An investor can expect a potential return of 98.27% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
The Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] reported sales of 450.71M for trailing twelve months, representing a surge of 40.83%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -0.01%, Pretax Profit Margin comes in at -0.19%, and Net Profit Margin reading is -0.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is 0.19 and Total Capital is -0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.91 points at the first support level, and at 7.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.17, and for the 2nd resistance point, it is at 8.27.
Ratios To Look Out For
It’s worth pointing out that Biocryst Pharmaceuticals Inc [NASDAQ:BCRX]’s Current Ratio is 2.63. Further, the Quick Ratio stands at 2.58, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 3.74.
Transactions by insiders
Recent insider trading involved Hutson Nancy J, Director, that happened on Dec 13 ’24 when 7000.0 shares were sold. Director, Hutson Nancy J completed a deal on Dec 13 ’24 to buy 7000.0 shares. Meanwhile, Director McKee Amy E sold 8600.0 shares on Jun 24 ’24.
